CARISMA Therapeutics Plunges 10.68% as HealthCap VII Sells Shares

On September 3, 2025, CARISMA Therapeutics experienced a significant drop of 10.68% in pre-market trading, reflecting a notable shift in investor sentiment.

HealthCap VII, a prominent investor in CARISMA Therapeutics, recently amended its Schedule 13D filing with the SEC, revealing multiple share sales. Notably, HealthCap VII sold 2,116,678 shares on September 2, 2025, which resulted in its stake falling below 5%. This substantial reduction in ownership by a major shareholder has likely contributed to the market's negative reaction, as investors may interpret this as a lack of confidence in the company's future prospects.

The SEC filings archive for September 2, 2025, indicates that there were 1,519 filings published on that date. While the archive provides a comprehensive view of corporate disclosures and regulatory filings, the specific details of HealthCap VII's share sales are particularly noteworthy for CARISMA Therapeutics investors. The reduction in HealthCap VII's stake, coupled with the broader market's response, suggests that investors are closely monitoring the company's developments and may be reassessing their positions accordingly.